Skip to content

Thursday, August 13, 2026

Latest:

CS18: a new drug that can potentially overcome cancer drug resistance
The sunburn your child won’t forget
Next-gen probiotics to support space exploration
BCM-led team awarded inaugural Burroughs Wellcome Fund Climate Health Center of Excellence Grant to advance climate and health research
Welcome new School of Medicine, Graduate School and School of Health Professions students!

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

CS18

CS18: a new drug that can potentially overcome cancer drug resistance

August 13, 2026 Breast Cancer, Cancer, CS18, osimertinib, PARP inhibitors, Research, therapy resistance, TopBP1

CS18 is a candidate for further development as a drug that could become part of combination treatments to prevent or overcome cancer drug resistance.

From the Labs: Image of the Month

From the Labs: Tau travels between neurons

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951